MINNEAPOLIS, Feb. 26, 2013 /PRNewswire/ -- BioDrain Medical, Inc., (OTCQB: BIOR), producer of the FDA approved STREAMWAY® System for automated, direct-to-drain surgical fluid disposal that reduces the risk of exposure to hazardous waste, announced today that it will exhibit its breakthrough technology at the 60th Annual Association of periOperative Registered Nurses (AORN) Congress in San Diego in March.
BioDrain will showcase the Company's groundbreaking FDA approved STREAMWAY System from March 4 6, 2013 at the San Diego Convention Center in San Diego, California at booth #1520.
Today's manual surgical fluid handling method, which means hand-carrying surgical fluid canisters and emptying these canisters into drains and sinks, creates a great exposure risk and is an antiquated approach to the handling of surgical fluid waste. BioDrain's STREAMWAY System is a direct-to-drain product that is a stationary system installed into each surgical room and hooked into a hospital's existing drain and vacuum system. Unlike other fluid management options, the STREAMWAY System has continuous suction and unlimited capacity.
"We are experiencing a rapid upswing in awareness about our flagship technology as hospitals search for safer and more efficient ways to dispose of surgical fluids. Demonstrating the STREAMWAY System at the AORN Congress is a great opportunity to share this technology with the healthcare personnel who are on the front lines when it comes to removing surgical waste after procedures," said Josh Kornberg, Chief Executive Officer at BioDrain Medical. "These are the people who will truly understand the impact of an automated direct-to-drain system for them it means less time and less risk of exposure to potentially dangerous materials."
"The feedback we get from nurses and doctors is resoundingly positive. The STREAMWAY System improves operating room safety by offering a cleaner, safer surgical fluid disposal solution that is more reliable and less expensive than the existing manual processes," continued Mr. Kornberg. "In fact, 100 percent of our trial installations have resulted in a sale of the system, so we believe that offering AORN Congress participants the chance to interface with the technology will help thousands of healthcare leaders realize the positive impact the STREAMWAY System can have on their practicesin terms of budget, safety, ease-of-use and environmental mindfulness."
For additional information about the Company, please visit: www.biodrainmedical.com.
About BioDrain Medical
BioDrain Medical, Inc. has a fully automated, patented, FDA cleared, surgical fluid disposal system that virtually eliminates operating room workers' exposure to blood, irrigation fluid and other potentially infectious fluids found in the surgical environment. Today's manual surgical fluid handling methods of hand-carrying filled surgical fluid canisters and emptying these canisters is an exposure risk and an antiquated approach to the handling of surgical fluid waste. BioDrain's STREAMWAY System fully automates the collection, measurement and disposal of surgical fluids and is designed to result in: 1) reducing overhead costs to hospitals and surgical centers, 2) improving Occupational State and Health Association (OSHA) and other regulatory compliance agencies' safety concerns, and 3) streamlining the efficiency of the operating room (and thereby making surgeries more profitable).
BioDrain's STREAMWAY System is eco-friendly as it contributes to cleaning up the environment. Currently, approximately 50 million bloody, potentially disease infected canisters go to landfills annually in the United States. These tainted canisters can remain in landfills for years to come. With the installation of BioDrain's STREAMWAY System, the number of canisters can be significantly reduced. BioDrain Medical, Inc. makes the operating room and our environment safer, cleaner, and better. BioDrain products are currently being represented by independent professional sales representatives that cater to the needs of hospitals and ambulatory surgical centers across the country. For additional information, please visit: www.biodrainmedical.com.
Certain of the matters discussed in this announcement contain forward-looking statements that involve material risks to and uncertainties in the company's business that may cause actual results to differ materially from those anticipated by the statements made herein. Such risks and uncertainties include, among other things, our ability to establish and maintain the proprietary nature of our technology through the patent process, as well as our ability to possibly license from others patents and patent applications necessary to develop products; the availability of financing; the company's ability to implement its long range business plan for various applications of its technology; the company's ability to enter into agreements with any necessary marketing and/or distribution partners; the impact of competition, the obtaining and maintenance of any necessary regulatory clearances applicable to applications of the company's technology; and management of growth and other risks and uncertainties that may be detailed from time to time in the company's reports filed with the Securities and Exchange Commission. This is not a solicitation to buy or sell securities and does not purport to be an analysis of the company's financial position. See the company's most recent Quarterly Report on Form 10-Q and subsequent 8-K filings.
Public Relations Contact:
KCSA Strategic Communications
Investor Relations Contact:
KCSA Strategic Communications
SOURCE BioDrain Medical